| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on October 3, 2003
Accepted on December 15, 2003
From the First Department of Internal Medicine (T.H., A.I.) and the Third Department of Internal Medicine (S.K.), Showa University School of Medicine, Tokyo, Japan; the Research and Development Department (Y.I., H.S.), Denka Seiken Co. Ltd., Tokyo, Japan; and the Division of Cardiovascular Disease (M.T., J.Y.) and the Division of Diabetes, Metabolism, and Endocrinology (G.Y.), Department of Medicine, Toho University School of Medicine, Tokyo, Japan.
* To whom correspondence should be addressed. E-mail: hirano{at}med.showa-u.ac.jp.
Objective--Recently, we established a simple method for the quantification of small dense LDL cholesterol (C) using heparin-magnesium precipitation. The small dense LDL-C level was identical to cholesterol in the denser LDL fraction with a density of 1.044 to 1.063 g/mL. The aim of this study was to examine clinical significance of this precipitation method for small dense LDL-C.
Methods and Results--Small dense LDL-C was measured by a direct homogenous LDL-C assay in the supernatant that remained after heparin-magnesium precipitation with density <1.044 lipoproteins. In 313 normolipidemic subjects, the mean value of small dense LDL-C was 31±13 mg/dL. In 462 healthy subjects, small dense LDL-C levels were positively correlated with serum triglyceride and LDL-C and were inversely correlated with high-density lipoprotein cholesterol (HDL-C). Combined hyperlipidemia showed the highest small dense LDL-C level among the various types of hyperlipidemia. Patients with type 2 diabetes had an increased small dense LDL-C level (55±17). Patients with coronary heart disease also had increased small dense LDL-C levels (53±30) irrespective of the presence of diabetes, whereas their LDL-C levels were comparable to those of normolipidemic controls (111±31 versus 104±22).
Conclusion--These results suggest that measurement of small dense LDL-C by the present precipitation method is useful to evaluate atherogenic risk and may be applicable to routine clinical examination.
This article has been cited by other articles:
![]() |
B. Zhang, A. Matsunaga, D. L. Rainwater, S.-i. Miura, K. Noda, H. Nishikawa, Y. Uehara, K. Shirai, M. Ogawa, and K. Saku Effects of rosuvastatin on electronegative LDL as characterized by capillary isotachophoresis: the ROSARY Study J. Lipid Res., September 1, 2009; 50(9): 1832 - 1841. [Abstract] [Full Text] [PDF] |
||||
|
ATVB Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2004 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |